175 related articles for article (PubMed ID: 38779676)
1. Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B.
Jiang Y; Wang R; Guo J; Cheng K; Chen L; Wang X; Li Y; Du P; Gao C; Lu J; Yu Y; Yang Z
Front Immunol; 2024; 15():1380694. PubMed ID: 38779676
[TBL] [Abstract][Full Text] [Related]
2. Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B.
Rasetti-Escargueil C; Avril A; Chahboun S; Tierney R; Bak N; Miethe S; Mazuet C; Popoff MR; Thullier P; Hust M; Pelat T; Sesardic D
MAbs; 2015; 7(6):1161-77. PubMed ID: 26381852
[TBL] [Abstract][Full Text] [Related]
3. Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain.
Avril A; Miethe S; Popoff MR; Mazuet C; Chahboun S; Rasetti-Escargueil C; Sesardic D; Thullier P; Hust M; Pelat T
BMC Biotechnol; 2015 Sep; 15():86. PubMed ID: 26382731
[TBL] [Abstract][Full Text] [Related]
4. Design and evaluation of mRNA encoding recombinant neutralizing antibodies for botulinum neurotoxin type B intoxication prophylaxis.
Qiaerxie G; Jiang Y; Li G; Yang Z; Long F; Yu Y; Lu JS; Du P; Cui Y
Hum Vaccin Immunother; 2024 Dec; 20(1):2358570. PubMed ID: 38853516
[TBL] [Abstract][Full Text] [Related]
5. Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library.
Miethe S; Rasetti-Escargueil C; Liu Y; Chahboun S; Pelat T; Avril A; Frenzel A; Schirrmann T; Thullier P; Sesardic D; Hust M
MAbs; 2014; 6(2):446-59. PubMed ID: 24492304
[TBL] [Abstract][Full Text] [Related]
6. Enhancing toxin-based vaccines against botulism.
Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.
Shi DY; Lu JS; Mao YY; Liu FJ; Wang R; Du P; Yu S; Yu YZ; Yang ZX
Appl Microbiol Biotechnol; 2023 May; 107(10):3205-3216. PubMed ID: 37058230
[TBL] [Abstract][Full Text] [Related]
8. Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B.
Miethe S; Mazuet C; Liu Y; Tierney R; Rasetti-Escargueil C; Avril A; Frenzel A; Thullier P; Pelat T; Urbain R; Fontayne A; Sesardic D; Hust M; Popoff MR
PLoS One; 2016; 11(8):e0161446. PubMed ID: 27560688
[TBL] [Abstract][Full Text] [Related]
9. Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B.
Matsumura T; Amatsu S; Misaki R; Yutani M; Du A; Kohda T; Fujiyama K; Ikuta K; Fujinaga Y
Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32392791
[TBL] [Abstract][Full Text] [Related]
10. In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH).
Bakherad H; Mousavi Gargari SL; Rasooli I; Rajabibazl M; Mohammadi M; Ebrahimizadeh W; Safaee Ardakani L; Zare H
Mol Biotechnol; 2013 Oct; 55(2):159-67. PubMed ID: 23666874
[TBL] [Abstract][Full Text] [Related]
11. Preparation of egg yolk antibodies against BoNT/B and their passive protection in mouse models.
You Z; Yang H; Xin W; Kang L; Gao S; Wang J; Zhang T; Wang J
Hum Vaccin Immunother; 2014; 10(8):2321-7. PubMed ID: 25424938
[TBL] [Abstract][Full Text] [Related]
12. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.
Levy R; Forsyth CM; LaPorte SL; Geren IN; Smith LA; Marks JD
J Mol Biol; 2007 Jan; 365(1):196-210. PubMed ID: 17059824
[TBL] [Abstract][Full Text] [Related]
13. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library.
Yu R; Wang S; Yu YZ; Du WS; Yang F; Yu WY; Sun ZW
J Biomol Screen; 2009 Sep; 14(8):991-8. PubMed ID: 19726786
[TBL] [Abstract][Full Text] [Related]
15. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
[TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B.
Shi DY; Chen BY; Mao YY; Zhou G; Lu JS; Yu YZ; Zhou XW; Sun ZW
Hum Vaccin Immunother; 2019; 15(3):755-760. PubMed ID: 30433836
[TBL] [Abstract][Full Text] [Related]
17. Characterization of neutralizing mouse-human chimeric and shuffling antibodies against botulinum neurotoxin A.
Mukamoto M; Maeda H; Kohda T; Nozaki C; Takahashi M; Kozaki S
Microbiol Immunol; 2012 Nov; 56(11):748-55. PubMed ID: 22938032
[TBL] [Abstract][Full Text] [Related]
18. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
Fan Y; Barash JR; Lou J; Conrad F; Marks JD; Arnon SS
J Infect Dis; 2016 May; 213(10):1606-14. PubMed ID: 26936913
[TBL] [Abstract][Full Text] [Related]
19. Production of a neutralizing mouse-human chimeric antibody against botulinum neurotoxin serotype E.
Mukamoto M; Maeda H; Kohda T; Nozaki C; Takahashi M; Kozaki S
Jpn J Infect Dis; 2013; 66(1):46-50. PubMed ID: 23429085
[TBL] [Abstract][Full Text] [Related]
20. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR
PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
